XML 59 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue      
Total revenues $ 131,314 $ 196,245 $ 241,544
Royalties      
Disaggregation of Revenue      
Total revenues 83,910 72,527 48,927
Kyprolis      
Disaggregation of Revenue      
Total revenues 35,640 30,116 27,472
Evomela      
Disaggregation of Revenue      
Total revenues 10,212 10,197 10,079
Teriparatide injection      
Disaggregation of Revenue      
Total revenues 11,061 15,785 5,260
Rylaze      
Disaggregation of Revenue      
Total revenues 13,520 8,796 2,420
Other      
Disaggregation of Revenue      
Total revenues 13,477 7,633 3,696
Captisol      
Disaggregation of Revenue      
Total revenues 28,372 104,495 164,250
Captisol - Core      
Disaggregation of Revenue      
Total revenues 28,372 16,429 23,423
Captisol - COVID      
Disaggregation of Revenue      
Total revenues 0 88,066 140,827
Contract      
Disaggregation of Revenue      
Total revenues 19,032 19,223 28,367
Service Revenue      
Disaggregation of Revenue      
Total revenues 615 1,117 3,737
License Fees      
Disaggregation of Revenue      
Total revenues 217 2,849 634
Milestone      
Disaggregation of Revenue      
Total revenues 16,800 9,150 17,584
Other      
Disaggregation of Revenue      
Total revenues $ 1,400 $ 6,107 $ 6,412